BTC Capital Management Inc. cut its holdings in Sanofi (NASDAQ:SNY – Free Report) by 1.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,229 shares of the company’s stock after selling 434 shares during the period. BTC Capital Management Inc.’s holdings in Sanofi were worth $1,361,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of SNY. Synergy Asset Management LLC purchased a new stake in Sanofi during the 4th quarter valued at $25,000. Northwest Investment Counselors LLC purchased a new position in shares of Sanofi during the 3rd quarter worth approximately $29,000. Concord Wealth Partners raised its holdings in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares in the last quarter. Fortitude Family Office LLC increased its stake in shares of Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares in the last quarter. Finally, Sunbelt Securities Inc. lifted its holdings in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $60.00.
Sanofi Stock Performance
Shares of SNY opened at $54.15 on Friday. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The stock has a market cap of $137.42 billion, a price-to-earnings ratio of 27.63, a PEG ratio of 1.21 and a beta of 0.57. The business has a 50-day simple moving average of $49.12 and a two-hundred day simple moving average of $52.24.
Sanofi (NASDAQ:SNY – Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. On average, analysts expect that Sanofi will post 3.82 EPS for the current year.
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
See Also
- Five stocks we like better than Sanofi
- 3 Monster Growth Stocks to Buy Now
- 3 Turnaround Stocks in the Early Innings With More Upside to Come
- 5 Top Rated Dividend Stocks to Consider
- Whirlpool: Buy This High-Yielding Value Before It Spins Higher
- How to Start Investing in Real Estate
- Commvault Systems: Share Price Primed to Vault Higher in 2025
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.